Literature DB >> 17553616

Cell killing by antibody-drug conjugates.

Yelena V Kovtun1, Victor S Goldmacher.   

Abstract

Antibody-drug conjugates (ADCs) are designed to specifically bind to and kill cells expressing their target antigens. In addition to the obvious requirement of the presence of the target antigen on the cell surface, several other factors contribute to the sensitivity of target cells to the action of ADCs. These include (i) the rate of internalization of the ADC, (ii) its proteolytic degradation in late endosomes and lysosomes and the subsequent release of cytotoxic drug, and (iii) the intracellular concentration of the released drug. In addition to killing antigen-expressing cells, some ADCs were found to kill bystander cells irrespective of their antigen expression. This review summarizes the current knowledge of the mechanisms of killing of antigen-expressing and bystander cells by antibody-drug conjugates.

Mesh:

Substances:

Year:  2007        PMID: 17553616     DOI: 10.1016/j.canlet.2007.04.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

Review 1.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

Review 3.  Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Authors:  S Sadekar; I Figueroa; M Tabrizi
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

4.  Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.

Authors:  M Benjamin Hock; Karen E Thudium; Montserrat Carrasco-Triguero; Nikolai F Schwabe
Journal:  AAPS J       Date:  2014-11-08       Impact factor: 4.009

Review 5.  Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.

Authors:  Jessica R McCombs; Shawn C Owen
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

Review 6.  Antibody Drug Conjugates: Preclinical Considerations.

Authors:  Gadi G Bornstein
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

7.  Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.

Authors:  Shan Yu; Aaron D Pearson; Reyna Kv Lim; David T Rodgers; Sijia Li; Holly B Parker; Meredith Weglarz; Eric N Hampton; Michael J Bollong; Jiayin Shen; Claudio Zambaldo; Danling Wang; Ashley K Woods; Timothy M Wright; Peter G Schultz; Stephanie A Kazane; Travis S Young; Matthew S Tremblay
Journal:  Mol Ther       Date:  2016-10-12       Impact factor: 11.454

Review 8.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

Review 9.  Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.

Authors:  Girgis Obaid; Mans Broekgaarden; Anne-Laure Bulin; Huang-Chiao Huang; Jerrin Kuriakose; Joyce Liu; Tayyaba Hasan
Journal:  Nanoscale       Date:  2016-06-20       Impact factor: 7.790

10.  Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.

Authors:  Khalid A Mohamedali; Gang Niu; Troy A Luster; Philip E Thorpe; Haokao Gao; Xiaoyuan Chen; Michael G Rosenblum
Journal:  Biochem Pharmacol       Date:  2012-09-26       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.